Cargando…

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?

Patients with long-standing ulcerative colitis (UC) and extensive Crohn’s colitis (CC) are at increased risk for dysplasia and colorectal cancer (CRC). Several studies have shown that UC extending proximal to the rectum, CC involving at least 1/3 of the colon, co-existence of primary sclerosing chol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galanopoulos, Michail, Tsoukali, Emmanouela, Gkeros, Filippos, Vraka, Marina, Karampekos, Georgios, Matzaris, Gerassimos J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198309/ https://www.ncbi.nlm.nih.gov/pubmed/30364842 http://dx.doi.org/10.4253/wjge.v10.i10.250

Ejemplares similares

COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract
por: Galanopoulos, Michail, et al.
Publicado: (2020)

Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
por: Galanopoulos, Michail, et al.
Publicado: (2021)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Optimising inflammatory bowel disease surveillance and dysplasia management—Where do we stand?
por: Al Bakir, Ibrahim, et al.
Publicado: (2022)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease
por: Shukla, Richa, et al.
Publicado: (2017)

Artificial intelligence and inflammatory bowel disease: Where are we going?
por: Da Rio, Leonardo, et al.
Publicado: (2023)

Secondary metastatic lesions to colon and rectum
por: Galanopoulos, Michail, et al.
Publicado: (2018)

Microbiological surveillance – where do we stand?
por: Beilenhoff, Ulrike
Publicado: (2023)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget
por: Núñez F, Paulina, et al.
Publicado: (2022)

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature
por: Ghosn, Marwan, et al.
Publicado: (2016)

Where Do We Stand?
Publicado: (1891)

Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract
por: Galanopoulos, Michail, et al.
Publicado: (2020)

Sessile serrated adenoma/polyps: Where are we at in 2016?
por: Singh, Rajvinder, et al.
Publicado: (2016)

Endoscopic therapy for Barrett’s esophagus and early esophageal cancer: Where do we go from here?
por: Singh, Tavankit, et al.
Publicado: (2018)

Role of endoscopic ultrasound in vascular interventions: Where are we now?
por: Fugazza, Alessandro, et al.
Publicado: (2022)

Selenium, Stroke, and Infection: A Threefold Relationship; Where Do We Stand and Where Do We Go?
por: Liampas, Andreas, et al.
Publicado: (2023)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Active surveillance in prostate cancer management: where do we stand now?
por: Dragan, Jędrzej, et al.
Publicado: (2020)

Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management?
por: Samo, Salih, et al.
Publicado: (2019)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

The Management of Posterior Malleolus Fractures in Unstable Ankle Injuries: Where Do We Stand Now?
por: Serlis, Athanasios, et al.
Publicado: (2022)

Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
por: Lin, Te-Fu, et al.
Publicado: (2018)

Circulating tumor DNA: Where are we now? A mini review of the literature
por: Galarza Fortuna, Gliceida Maria, et al.
Publicado: (2020)

EEG Recordings as Biomarkers of Pain Perception: Where Do We Stand and Where to Go?
por: Zis, Panagiotis, et al.
Publicado: (2022)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

The Role of Carrageenan in Inflammatory Bowel Diseases and Allergic Reactions: Where Do We Stand?
por: Borsani, Barbara, et al.
Publicado: (2021)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Potential of laser‐induced fluorescence‐light detection and ranging for future stand‐off virus surveillance
por: Owoicho, Oloche, et al.
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_mrtofprt7jf0kadvasgvhau89j